Benign in Biological Technology
Navigation Links
Benign in Biological Technology
... study (study 041) of its Phase 3 program in benign prostatic hyperplasia (BPH) with its lead ... controlled efficacy study (study 033). BPH is a benign enlargement of the prostate, affecting more than ... as well as in Japan through Shionogi.
About benign Prostatic Hyperplasia
...
... The major difference between the studies is the benign toxicity profile reported with nimotuzumab. No ... inhibitors in the presence of an astonishingly benign safety profile. The toxicity/benefit correlation ... EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor ...
... patients with prostate cancer from those who have benign prostate hyperplasia, a common condition whose ... been found in normal individuals or those with benign prostate hyperplasia (BPH). However, multiple ... to identify patients with prostate cancer vs. benign prostatic hyperplasia (BPH). Although work is ...
... registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. ... as well as in Japan through Shionogi. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
... opened its doors to patients diagnosed with both benign and malignant brain tumors. In a move that ... make major breakthroughs in the treatment of both benign and malignant brain tumors," said Marc Mayberg, ... care and innovative treatments for both benign and malignant brain tumors. CABTT's unique design ...
... second efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous ... in both North America and Europe. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
... first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous ... in both North America and Europe. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
... physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more ... The report entitled Treatment Algorithms in benign Prostatic Hyperplasia also finds that slightly ... than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients ...
... which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by European regulatory ... and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and ....
... journals and discussion of the studies with regulatory agencies. benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most common diseases of aging ...
... journals and discussion of the studies with regulatory agencies. benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most common diseases of aging ...
... independent validation of a marker panel for distinguishing benign from malignant pelvic masses." The abstract, which demonstrated that ... Triage Test to differentiate women with ovarian cancer from women with benign pelvic masses. -- Presented seven studies at the European Society for ...
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...
... with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more than 3,500 patients ...
... with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in over 12 countries, In more than 3,500 patients ...
... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
... with cetrorelix pamoate for the treatment of benign prostatic hyperplasia (BPH), a benign enlargement of the prostate, affecting more than ... as well as in Japan through Shionogi. About benign Prostatic Hyperplasia ...... The major difference between the studies is the benign toxicity profile reported with nimotuzumab. No ... inhibitors in the presence of an astonishingly benign safety profile. The toxicity/benefit correlation ... EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor ...
... patients with prostate cancer from those who have benign prostate hyperplasia, a common condition whose ... been found in normal individuals or those with benign prostate hyperplasia (BPH). However, multiple ... to identify patients with prostate cancer vs. benign prostatic hyperplasia (BPH). Although work is ...
Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
... of the TRPM8 Ion Channel Agonist D-3263 for benign Prostatic Hyperplasia." Poster presentation to occur in the benign Prostatic Hyperplasia: Basic Research session. ... applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its ...... registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. ... as well as in Japan through Shionogi. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
... Validation of the TrpM8 Ion Channel as a Cancer/ benign Prostate Hyperplasia Target," was presented at ... therapy for cancer and also potentially for benign prostatic hyperplasia (BPH)," said David Urdal, ... applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has ...... opened its doors to patients diagnosed with both benign and malignant brain tumors. In a move that ... make major breakthroughs in the treatment of both benign and malignant brain tumors," said Marc Mayberg, ... care and innovative treatments for both benign and malignant brain tumors. CABTT's unique design ...
... second efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous ... in both North America and Europe. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
... Detection and characterization of malignant and benign focal liver lesions with EOVIST may help enhance ... EOVIST, our ability to evaluate patients with benign and malignant focal hepatic lesions will be ... (i.e., distinction of malignant and benign types of liver lesions). EOVIST is marketed by ...AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
... hormone-releasing hormone (LHRH) antagonist in benign prostatic hyperplasia (BPH). Spectrum indicated ... of the studies with regulatory agencies. benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...... first efficacy trial of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous ... in both North America and Europe. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...
... physician's drug of choice for newly diagnosed benign prostatic hyperplasia patients. Garnering more ... The report entitled Treatment Algorithms in benign Prostatic Hyperplasia also finds that slightly ... than one-fifth (18.9 percent) of newly diagnosed benign prostatic hyperplasia patients ...
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
... second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous ... in both North America and Europe. About benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most ...New MRI technique could mean fewer breast biopsies in high-risk women
... and the contrast agent flows in and "leaks" out quickly. Conversely, benign lesions show more gradual in and out flow. "The tricky ones are the ... its shape. For example, breaks or interruptions in a lesion can indicate a benign fibroadenoma. Lumps with smooth edges often are benign, while those with ...Ausio Pharmaceuticals to Present at Bio(R) 2009
... safety studies, and plans for Phase 2 studies for menopausal symptoms and benign prostatic hyperplasia (BPH) are to be presented CINCINNATI, May 14 ... evaluated for a wide range of indications, including menopausal symptoms, benign prostatic hyperplasia, osteoporosis, and topical applications. ...YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
... 700 patients with cancers of the head and neck, citing the drug's benign safety profile. The trial is being supported by YM licensee, ... all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its ...Dendreon Reports First Quarter 2009 Financial Results
... channel protein), reduced the size of the prostate in an animal model of benign prostatic hyperplasia (BPH) alone or in combination with finasteride. ... TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, ...AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
... recruitment for the second efficacy trial of the Phase 3 program in benign prostatic hyperplasia (BPH) with lead compound, cetrorelix; - Start of ... which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by the European regulatory ...... which is currently in Phase 3 clinical trials for the treatment of benign prostatic hyperplasia, is approved for sale by European regulatory ... and Shionogi. Cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and ....
Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
... their office. The LIFE(TM) procedure is a breakthrough laser treatment for benign prostate hyperplasia (BPH) that quickly and gently removes blocking ... with the symptoms of frequent or difficult urination that are caused by a benign enlargement of the prostate. Every second man over 60 and nearly every man ...Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
... breakthrough LIFE(TM) (Laser Induced Flow Enhancement) laser treatment for benign prostate hyperplasia (BPH) that quickly and gently eliminates swollen ... with the symptoms of frequent or difficult urination that are caused by a benign enlargement of the prostate," says Kelly Moran, Chief Operating Officer ...... journals and discussion of the studies with regulatory agencies. benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most common diseases of aging ...
... journals and discussion of the studies with regulatory agencies. benign Prostatic Hyperplasia benign prostatic hyperplasia (BPH) is one of the most common diseases of aging ...
... independent validation of a marker panel for distinguishing benign from malignant pelvic masses." The abstract, which demonstrated that ... Triage Test to differentiate women with ovarian cancer from women with benign pelvic masses. -- Presented seven studies at the European Society for ...
Dendreon to Hold Conference Call on Tuesday, August 11, 2009 at 11:30 AM ET
... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...Neurocrine Biosciences Reports Second Quarter 2009 Results
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...
Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...
YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
... with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 18 countries. In more than 4000 patients reported as ...... with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in more than 12 countries. In more than 3,500 patients ...
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...... with radiation and chemoradiation. It is significantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in over 12 countries, In more than 3,500 patients ...
Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
... and provide additional cosmetic benefits such as smoother appearing skin. Additionally, Photopneumatic Therapy is also cleared for the treatment of benign vascular and pigmented lesions and hair removal. About Aesthera Corporation Aesthera ( www.AESTHERA.com ) develops, manufactures ...... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...
Dendreon Announces Closing of Common Stock Offering
... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
... Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine ...Dendreon Announces Common Stock Offering
... Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For ...Other ContentsshinglesshinglesstaturestaturestaturestatureshouldershouldershouldershouldershouldershouldershuntshuntshuntsicksicksicksickanemiaanemiaanemiaanemiaanemiaanemiaanemiaanemiaanemiasicklesicklesicklesicklesicklesigmoidsigmoidOther TagsTrainTrainTrainTrainTrainTrainMemoriesMysteriousPheromoneAmericanAmericanAmericanAmericanAmericanTransmissionTransmissionSports
(Date:12/4/2009)... measuring the total gene activity in organs relev...at the Swedish medical university Karolinska Insti...portant for the recruitment of white blood cells i...h are to be published in the open-access journal ...on of white blood cells in the development of athe...
(Date:12/4/2009)...e electroencephalogram (EEG) is widely used by phy... to diagnose neurological disorders. However, it h... on the head give an exact view of what is happeni...Institute for Biological Cybernetics in Tbingen, G...activity generated within the brain to that measur...
(Date:12/4/2009)...ing a new mathematical model of heart cells, Unive...ion of a critical enzyme, calmodulin kinase II (Ca...rt cells. , The study, which also involved Col...he journal PLoS Computational Biology . , "Rec...n calmodulin kinase II as a critical regulator of ...
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2How to read brain activity? 2U-Iowa study helps advance heart-related research 2Ability to process information as a baby continues into adulthood 53969 1Ability to process information as a baby continues into adulthood 53969 2Advances in lung cancer research announced at conference 9518 1Advances in lung cancer research announced at conference 9518 2GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 1GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 2GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 3GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 4GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 5GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 6GeoVax Labs Inc Announces Six Month 2009 Financial Results and Provides Operational Update 53964 7(Date:12/4/2009)..., PALO ALTO, Calif., Dec. 4 /PRNewswire-FirstCa...nced today that its Board of Directors has set the...ebruary 11, 2010 with a record date of December 16...za Cabana Hotel, 4290 El Camino Real, Palo Alto, C...be webcast by Thomson Financial and can be accesse...
(Date:12/4/2009)...YORK, Dec. 4 Care Inves...ompany") today announced that its Board of Directo...ommon stock. The dividend is payable on December ...ber 14, 2009. ,, About Care Investment Trus...te investment and finance company investing in hea...
(Date:12/4/2009)...EW YORK, Dec. 4 Thousands of KPMG ...s nationwide today, to participate in a community ...visory firm,s support for literacy with charitable...s our firm,s long history of volunteerism. Instead... spirit of caring to brighten the holidays for som...
(Date:12/4/2009)...N FRANCISCO, Dec. 4 Medithrive, In...ite dispensary in the SF Bay Area by popular vote .... Despite only three months in operation, the SF ...inent location for accessing medicinal marijuana. ...e confirms the obvious: a dispensary which caters ...
(Date:12/4/2009)... PEMBROKE, Bermuda, Dec. 4 /PRNewswire-FirstCall...(NYSE: AWH ) today announced that Scott Carmilan... Sennott, Executive Vice,President and Chief Corpo...009,Goldman Sachs U.S. Financial Services Conferen...er in New York City on Tuesday, December 8, 2009. ...
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2[0] Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto[0] Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share[0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children[0] Medithrive Voted #1 Medicinal Marijuana Dispensary in Bay Area[0] Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference
RearingSelectingTrainMemoriesFirefightersArcherfishMysteriousPheromoneSensoryAmericanSupercomputingTransmissionRescuingSports
Other Tagsregulating 2regulating 3regulating 4regulating 5regulating 6regulating 7regulating 8councils 2overcome 2overcome 3overcome 4overcome 5overcome 6overcome 7
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |